For research use only. Not for therapeutic Use.
Toreforant is a selective antagonist of the histamine H4 receptor, which is being investigated for its potential in treating inflammatory and allergic conditions, such as atopic dermatitis and asthma. By blocking the H4 receptor, toreforant can reduce the recruitment and activation of immune cells, leading to decreased inflammation and allergic responses. This targeted approach aims to provide therapeutic benefits with fewer side effects compared to broader-acting anti-inflammatory drugs, making toreforant a promising candidate in the treatment of chronic inflammatory diseases.
| Catalog Number | I009851 |
| CAS Number | 952494-46-1 |
| Synonyms | JNJ-38518168; JNJ 38518168; JNJ38518168; Toreforant.;5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl- N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine |
| Molecular Formula | C23H32N6 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine |
| InChI | InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26) |
| InChIKey | FCRFVPZAXGJLPW-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C |
